Thelansis

  HuidaGene Therapeutics (HuidaGene), a global clinical-stage biotechnology company specializing in genome medicines, has announced that the US FDA has cleared its HG202 investigational new drug (IND) application for neovascular age-related macular degeneration (nAMD). HG202 stands out as the first-ever clinical-stage CRISPR/Cas13 RNA-editing and the only RNA-targeting therapy for nAMD, marking a significant milestone in treating this condition. Publish Date: 04-11-2024   Source: HuidaGene Therapeutics Neovascular age-related macular degeneration (nAMD) represents one of the leading causes of blindness globally, with its prevalence projected to rise in conjunction with the aging population in various countries. The pathogenesis of nAMD is characterized by abnormal angiogenesis and macular neovascularization (MNV), also referred to as choroidal neovascularization (CNV), along with vascular leakage, hemorrhage, and scarring, which collectively contribute to irreversible...

  Neovascular age-related macular degeneration (nAMD) represents one of the leading causes of blindness globally, with its prevalence projected to rise in conjunction with the aging population in various countries. The pathogenesis of nAMD is characterized by abnormal angiogenesis and macular neovascularization (MNV), also referred to as choroidal neovascularization (CNV), along with vascular leakage, hemorrhage, and scarring, which collectively contribute to irreversible vision loss. Various mediators are implicated in this multifaceted process, including kinases, cytokines, and growth factors, with the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) being the most prominent. The advent of anti-VEGF agents, such as ranibizumab, bevacizumab, aflibercept, brolucizumab, and faricimab, has significantly transformed the clinical management of nAMD. However, an unmet clinical need persists for novel and enhanced therapies, as many patients exhibit suboptimal respo...